NCT03775577Recruiting
Exercise Intolerance in Heart Failure
Exercise Intolerance in Heart Failure: the Role of Altered Cardiac and Skeletal Muscle Energetics
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 130 (estimated)
- First submitted
- 1 Nov 2018
- Start date
- 1 Apr 2017
- Primary completion date
- Aug 2027
- Lead sponsor
- Johns Hopkins University
- Diseases
- Heart failure
- NCT number
- NCT03775577
What you commit to
- Study type: Observational
- Planned participants: 130
- From 1 Apr 2017 to the primary completion date, Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of clinical CAD or significant epicardial coronary disease (\>50% stenosis) in major coronary artery by x-ray or CT angiography unless (a) the patient underwent prior successful revascularization with percutaneous coronary angioplasty within the prior three years and (b) there are no residual lesions of \>50% on the most recent coronary angiographic study.
Other illness
- Contraindications to MRI such as implanted metallic objects (pre-existing cardiac pacemakers, cerebral clips) or indwelling metallic projectiles,
- History of infiltrative cardiomyopathy or constrictive pericarditis,
- Significant pulmonary disease,
- Any condition other than HF which could limit the ability to perform a 6MW or cardiopulmonary exercise test (CPET) test (e.g., critical peripheral vascular disease, significant orthopedic or neurological conditions),
- Any diseases other than HF which are likely to significantly alter the patient's global perception of status or quality of life over a period of 6 months.
- Significant peripheral vascular disease
Lab values
- Estimated glomerular filtration rate (eGFR) \<20ml/min,
Other
- Unable to understand the risks, benefits, and alternatives of participation and give meaningful consent,
- Significant valvular abnormalities,
- Pregnant women (women of childbearing potential will undergo blood or urine pregnancy testing),
- Cor pulmonale,
Who the study is looking for
- Patients of either gender who are greater than 21 years of age (no upper age limit),
- Permission of patient's clinical attending physician,
- Previous clinical diagnosis of HF with current New York Heart Association (NYHA) Class II-III symptoms for at least 1 month,
- Left ventricular ejection fraction (EF) \>50% by echocardiography, MRI, CT or x-ray or nuclear ventriculography within prior 12 months,
- Stable medical therapy for at least 30 days (no addition or removal or major (\>100%) dose change of Renin-Angiotensin-Aldosterone System (RAAS) antagonists, beta-blockers, or calcium channel blockers for hypertension).
Age in the registry: 21 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins Hospital Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.